Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Discovery Could Lead To New Treatment For Anxiety, Addiction

By Oregon Health & Science University | November 13, 2017

New research provides fresh insight into how the brain processes reward and punishment, opening new avenues for developing treatment of conditions ranging from anxiety to addictive behaviors such as drug abuse.

The study, published in the journal eLife, used a rodent model to identify a specific network within the brain closely tied to risk assessment.

“Our actions often involve varying risks of an aversive outcome. Our brains need to factor in this risk for optimal decision making,” said study author Bita Moghaddam, Ph.D., professor and chair of behavioral neuroscience in the OHSU School of Medicine, Portland, Oregon. “An exaggerated response to risk may lead to anxiety whereas an abnormally low response may lead to impulsivity and reckless behavior.” 

Moghaddam and co-author Junchol Park, Ph.D., at the University of Pittsburgh, found sharp distinctions in the level of coordination between a spike in dopamine neurons and activity within the prefrontal cortex, the portion of the brain that regulates complex cognitive functioning. They discovered close coordination between activity in the prefrontal cortex and dopamine levels when there was no risk of punishment – in this case, a food pellet dispensed in a chamber.

“In the real world, it’s almost never like that,” Moghaddam said. “Most of what we do involves risk.”

To that end, the researchers also measured brain activity in blocks of time when a small shock was administered 10 percent of the time. In sharp contrast to the no-punishment scenario, they found that coordination between the prefrontal cortex and dopamine levels collapsed when there was a small risk of punishment. Moghaddam said that may be a good thing because it means the brain encodes an ingrained assessment of risk in normal circumstances.

“There is a fine balance between normal functioning of risk assessment and harmful behaviors,” she said.

The study points the way toward additional research into behavioral or pharmaceutical treatments that may be effective in reducing either anxiety or impulsivity encoded within the physiology of the brain itself, Moghaddam said. She said the study suggests new avenues of research that could involve functional magnetic resonance imaging of people given risk-reward tasks such as gambling.

“Proper encoding of punishment risk and its contingency on actions and outcomes are fundamental to adaptive behavior and survival,” the authors concluded.

(Source: EurekAlert!)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50